Astrazeneca Ab

Charles Joseph Eyermann

Marshall Morningstar

Bolin Geng

Folkert Reck

Gloria Breault

Gregory Steven Basarab

Oluyinka Morenike Green

Lawrence MacPherson

Andrew Kiely

Nguyen Thanh

Madhu Gowravaram

The present invention relates to compounds of Formula V(A): that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds of Formula V(A) useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

Compounds for the treatment of multi-drug resistant bacterial infections

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

This invention relates to novel compounds having formula: (I) or (II) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis ofinfection.

Fused heterocycles as inhibitors of glutamate racemase(MURI)

Growing community of inventors

Waltham, MA, United States of America

Charles Joseph Eyermann